Glargine n = 708 Detemir n = 298 Glargine versus detemir
Characteristics n (%) n (%) Chi-square P value
Gender     0.12
   Male 397 (56) 151 (51)  
   Female 311 (44) 147 (49)  
Age, mean (SD), years 63 (13) 64 (13) <0.05
Prescriber     0.75
  General practitioner 350 (49) 144 (48)  
   Specialist 358 (51) 154 (52)  
Prior anti-diabeticsa      
   Insulinb 132 (19) 92 (31) <0.0001
   OADs 662 (94) 271 (91) 0.15
Concomitant OAD use 430 (61) 201 (67) <0.05
Comorbidityc      
   Any cardiovascular diseased 123 (17) 64 (21) 0.13
      Ischemic heart disease 98 (14) 47 (16) 0.43
      Cerebrovascular accident 32 (5) 15 (5) 0.72
      Peripheral vascular disease 6 (1) 5 (2) 0.25
   Congestive heart failure 17 (2) 10 (3) 0.39
   Chronic kidney disease 0 (0) 1 (<0.5) 0.12
Comedicatione      
   Antihypertensives 476 (67) 210 (70) 0.31
   Platelet inhibitors 264 (37) 110 (37) 0.91
   Nitrates 81 (11) 37 (12) 0.66
   Digoxin 31 (4) 15 (5) 0.65
SD, standard deviation; OADs, oral anti-diabetic drugs.
aIn year prior to cohort entry date.
bOther type of insulin than index treatment.
cBased on hospitalizations in the total available history.
dIschemic heart disease or cerebrovascular accident or peripheral vascular disease.
eBased on drug dispensings in the year before cohort entry date
.
Table 1: Patient baseline characteristics.